Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 5.15% is 188% above its 5-year average of -5.88%, near the high end of its 5-year range (-743.48%–37.72%).
60.16% below its 12-month average of 12.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 37.72%.
EBITDA MARGIN
5.15%
EBITDA MARGIN AVG TTM
12.93%
EBITDA MARGIN AVG 3Y
4.05%
EBITDA MARGIN AVG 5Y
-5.88%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-60.16%
CURRENT VS 3Y AVG
+27.05%
CURRENT VS 5Y AVG
+187.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Eton Pharmaceuticals, Inc.
Market Cap
$1.51B
EBITDA Margin
5.15%
TTM Avg
12.93%
3Y Avg
4.05%
5Y Avg
-5.88%
Market Cap
$1.52B
EBITDA Margin
33.84%
TTM Avg
32.51%
3Y Avg
-30.03%
5Y Avg
-1.40%
Market Cap
$1.48B
EBITDA Margin
16.46%
TTM Avg
14.25%
3Y Avg
12.03%
5Y Avg
12.13%
Market Cap
$1.48B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.54B
EBITDA Margin
-158.44%
TTM Avg
-796.42%
3Y Avg
-796.42%
5Y Avg
-1562.06%
Market Cap
$1.46B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | $1.51B | 5.15% | 12.93% | 4.05% | -5.88% |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 33.84% | 32.51% | -30.03% | -1.40% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 16.46% | 14.25% | 12.03% | 12.13% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 47.98% | 50.86% | 52.39% | 67.36% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -158.44% | -796.42% | -796.42% | -1562.06% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 36.35% | 36.35% | 36.35% | 36.35% |
| Certara, Inc. (CERT)vs › | $1.46B | 18.52% | 17.87% | 16.34% | 15.57% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -74.29% | -81.81% | -115.58% | -114.07% |
Gross Margin
57.9%
EBITDA Margin
5.2%
Operating Margin
0.1%
Net Margin
12.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 37.72% |
| 2026-03-31 | 14.61% |
| 2025-12-31 | 16.36% |
| 2025-09-30 | -1.58% |
| 2025-06-30 | -2.48% |
| 2025-03-31 | 3.14% |
| 2024-12-31 | 8.45% |
| 2024-09-30 | 7.62% |
| 2024-06-30 | -29.27% |
| 2024-03-31 | -7.11% |
| 2023-12-31 | -23.49% |
| 2023-09-30 | -5.08% |
| 2023-06-30 | 33.80% |
| 2023-03-31 | -43.76% |
| 2022-12-31 | 15.46% |
| 2022-09-30 | -84.65% |
| 2022-06-30 | -2.30% |
| 2022-03-31 | -225.46% |
| 2021-12-31 | 23.81% |
| 2021-09-30 | -743.48% |
| 2021-06-30 | -73.04% |
| 2021-03-31 | 46.38% |
| 2020-12-31 | -8961.73% |
| 2020-09-30 | 3793.79% |
| 2020-06-30 | -21870.00% |
| 2020-03-31 | -8807.07% |
| 2019-12-31 | -546.41% |
| 2019-03-31 | -1499.80% |
